相关实验视频

Updated: Jun 25, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

基于ksanthine的DPP-4抑制剂的设计:一个结构导向对齐依赖的多面 3D-QSAR建模,以及分子动力学模拟研究

Priya Bisht¹, Priyadarshi Gautam¹, Arka Bhattacharya¹

¹Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.

Journal of biomolecular structure & dynamics

|May 24, 2024

概括

新的基于山丁的分子显示出作为二二酶-4 (DPP-4) 抑制剂的潜力,用于2型糖尿病. 这些化合物表现出优越的结合能和稳定性,相比药物林格利平,这表明潜在的新药开发.

科学领域:

药用化学医学化学
计算化学计算化学
药理学药理学是指药理学的学科.

背景情况:

双基化酶-4 (DPP-4) 酶降解了内激素,影响了葡萄糖的调节.
DPP-4 抑制剂对于管理2型糖尿病至关重要.
基于丁支架的分子,如林格利普丁,已被确立为DPP-4抑制剂.

研究的目的:

作为潜在的DPP-4抑制剂,对丁衍生物进行结构导向,对齐依赖的3D-QSAR.
为了产生药理学假设并分析结构-活性关系 (SAR).
用分子动力学模拟来评估强效化合物的结合能和稳定性.

主要方法:

使用基于原子和高斯字段的描述器开发多方面的3D-QSAR模型.
验证QSAR模型的可靠性和预测准确性.
分子动力学 (MD) 模拟和MM-PBSA计算用于具有约束力的自由能量估计.

主要成果:

成功开发出具有统计意义和预测性的多方面的3D-QSAR模型.
药测绘确定了DPP-4抑制的关键特征.
化合物12,40和57的结合自由能量和稳定性明显优于林格利平.

结论:

这项研究提供了对基于ksanthine的DPP-4抑制剂SAR的见解.
MD模拟证实了新型化合物的增强的结合亲和力和稳定性.
这些发现支持设计新的,选择性的基于山丁的DPP-4抑制剂,用于治疗2型糖尿病.

关键词:

基于原子的3D-QSAR.DPP-4 抑制剂的使用基于高斯的现场3D-QSAR.分子对接的分子对接.分子动力学模拟模拟

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...